表紙
企業レポート

PharmaPoint:ドライアイ症候群(DES)- 現在/将来の市場参入企業

PharmaPoint: Dry Eye Syndrome - Current and Future Players

発行 GlobalData 商品コード 281777
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
PharmaPoint:ドライアイ症候群(DES)- 現在/将来の市場参入企業 PharmaPoint: Dry Eye Syndrome - Current and Future Players
出版日: 2013年05月31日 ページ情報: 英文 45 Pages
概要

当レポートでは、ドライアイ症候群(DES)治療薬について調査分析し、現在/将来の市場参入企業の現状と促進要因に焦点を当てて、競合分析、企業プロファイルなどを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場見通し

  • 世界市場
    • 予測
    • 促進要因・障壁

第4章 現在/将来の市場参入企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • Allergan
    • Alcon(Novartis AG の完全子会社)
    • 参天製薬
    • Shire/SARcode Bioscience
    • 大塚ホールディングス
    • Can-Fite Biopharma
    • Eyegate Pharma

第5章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1016FPR

Summary

GlobalData has released its pharma report, "PharmaPoint: Dry Eye Syndrome - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing DES Market. The report identifies and analyses the key companies shaping and driving the global DES market. The report provides insight into the competitive DES landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation.

Scope

  • Investigation of current and future market competition for DES
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of DES sector through market impact analysis, future market scenario and company analysis.

Reasons to buy

  • Gain a high level view of the trends shaping and driving DES Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global DES market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Allergan
    • 4.3.2. Alcon (a wholly-owned subsidiary of Novartis AG)
    • 4.3.3. Santen Pharmaceutical
    • 4.3.4. Shire/SARcode Bioscience
    • 4.3.5. Otsuka Holdings
    • 4.3.6. Can-Fite Biopharma
    • 4.3.7. Eyegate Pharma

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Diagnosed DES patients
    • 5.4.2. Percent Drug-treated Patients
    • 5.4.3. Drugs Included in Each Therapeutic Class
    • 5.4.4. Launch and Patent Expiry Dates
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Drug Assumptions
    • 5.4.7. Generic Erosion
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. About the Authors
    • 5.6.1. Author
    • 5.6.2. Global Head of Healthcare
  • 5.7. About GlobalData
  • 5.8. Contact Us
  • 5.9. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Dry Eye Syndrome, 2012-2022
  • Table 2: Dry Eye Syndrome Global Market - Drivers and Barriers, 2012-2022
  • Table 3: Key Companies in the Dry Eye Syndrome Market, 2012
  • Table 4: Allergan's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 5: Allergan SWOT Analysis, 2012
  • Table 6: Alcon's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 7: Alcon's Dry Eye Syndrome Portfolio SWOT Assessment, 2012
  • Table 8: Santen Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 9: Santen Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 10: Santen Pharmaceutical's Dry Eye Syndrome Portfolio SWOT Analysis, 2012
  • Table 11: Shire's Dry Eye Syndrome Portfolio Assessment, 2013
  • Table 12: Shire's Dry Eye Syndrome Portfolio SWOT Analysis, 2013
  • Table 13: Otsuka Pharmaceutical's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 14: Otsuka Pharmaceutical's Dry Eye Syndrome Portfolio SWOT Analysis, 2012
  • Table 15: Can-Fite Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 16: Can-Fite's Dry Eye Syndome Portfolio SWOT Analysis, 2012
  • Table 17: Eyegate Pharma's Dry Eye Syndrome Portfolio Assessment, 2012
  • Table 18: Eyegate Pharma's Dry Eye Syndrome Portfolio SWOT Analysis, 2012
  • Table 19: Key Launch Dates
  • Table 20: Key Patent Expiries

List of Figures

  • Figure 1: Global Sales for Dry Eye Syndrome by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Dry Eye Syndrome, 2012-2022
Back to Top